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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure 
that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the 
results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Italian language.
The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was 
asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen 
in a 6-month period and to administer the JAMAR to 100 healthy children and their parents.
The statistical validation phase explored descriptive statistics and the psychometric issues of the JAMAR: the 3 Likert 
assumptions, floor/ceiling effects, internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and 
construct validity (convergent and discriminant validity).
A total of 1296 JIA patients (7.2% systemic, 59.5% oligoarticular, 21.4% RF negative polyarthritis, 11.9% other categories) 
and 100 healthy children, were enrolled in 18 centres. The JAMAR components discriminated well healthy subjects from 
JIA patients except for the Health Related Quality of Life (HRQoL) Psychosocial Health (PsH) subscales. All JAMAR 
components revealed good psychometric performances.
In conclusion, the Italian version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use 
both in routine clinical practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Italian parent, child/adult version of the 
Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthritis 
(JIA). The JAMAR assesses the most relevant parent/patient 
reported outcomes in JIA, including overall well-being, 
functional status, Health Related Quality of Life (HRQoL), 
pain, morning stiffness, disease activity/status/course, 
articular and extra-articular involvement, drug-related side 
effects/compliance and satisfaction with illness outcome.
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This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Italian language.
Materials and methods
The methodology employed has been described in detail 
in the introductory paper of the supplement [4]. In brief, 
it was a cross-sectional study of JIA children, classified 
according to the ILAR criteria [5, 6] and enrolled from 
January 2012 to April 2016. Children were recruited after 
Ethics Committee approval and consent from at least one 
parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. Assessment of physical function (PF) using 15-items 
in which the ability of the child to perform each task is 
scored as follows: 0 = without difficulty, 1 = with some 
difficulty, 2 = with much difficulty, 3 = unable to do and 
not applicable if it was not possible to answer the ques-
tion or the patient was unable to perform the task due 
to their young age or to reasons other than JIA. The 
total PF score ranges from 0 to 45 and has 3 com-
ponents: PF-lower limbs (PF-LL); PF-hand and wrist 
(PF-HW) and PF-upper segment (PF-US) each scor-
ing from 0 to 15 [7]. Higher scores indicating higher 
degree of disability [8–10];
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11];
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint);
 4. Assessment of morning stiffness (present/absent);
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent);
 6. Rating of the level of disease activity on a 21-circle 
VAS;
 7. Rating of disease status at the time of the visit (cat-
egorical scale);
 8. Rating of disease course from previous visit (categori-
cal scale);
 9. Checklist of the medications the patient is taking (list 
of choices);
 10. Checklist of side effects of medications;
 11. Report of difficulties with medication administration 
(list of items);
 12. Report of school/university/work problems caused by 
the disease (list of items);
 13. Assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) subscales (5 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14];
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS;
 15. A question about satisfaction with the outcome of the 
illness (yes/no) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The original Italian JAMAR [1] was only modified in format 
and in the order of items. Cross-cultural adaptation was not 
deemed necessary for this version of the questionnaire, since 
it was routinely administered to JIA patients and to their 
parents since 2007 at the Italian PRINTO National Coordi-
nating Center in Genoa.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period. The PRINTO National Coordinating Center was 
asked to administer the JAMAR to 100 healthy children and 
their parents.
The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Lik-
ert assumption [mean and standard deviation (SD) equiva-
lence]; the second Likert assumption or equal items–scale 
correlations (Pearson r: all items within a scale should con-
tribute equally to the total score); third Likert assumption 
(item internal consistency or linearity for which each item 
of a scale should be linearly related to the total score that is 
90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes of 
the scales, respectively); internal consistency, measured by 
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the Cronbach’s alpha, interscale correlation (the correlation 
between two scales should be lower than their reliability 
coefficients, as measured by Cronbach’s alpha); test–retest 
reliability or intra-class correlation coefficient (reproducibil-
ity of the JAMAR repeated after 1 or 2 weeks); and construct 
validity in its two components: the convergent or external 
validity which examines the correlation of the JAMAR sub-
scales with the 6 JIA core set variables, with the addition 
of the parent assessment of disease activity and pain by the 
Spearman’s correlation coefficients (r) [17] and the discri-
minant validity, which assesses whether the JAMAR dis-
criminates between the different JIA categories and healthy 
children [18]. Quantitative data were reported as medians 
with 1st and 3rd quartiles and categorical data as absolute 
frequencies and percentages.
The complete Italian parent and patient versions of the 
JAMAR are available upon request to PRINTO.
Results
Demographic and clinical characteristics 
of the subjects
A total of 1300 JIA patients and 100 healthy children (total 
of 1400 subjects), were enrolled at 18 paediatric rheumatol-
ogy centres. Four patients did not give the consent to use 
their data.
In the remaining 1296/1300 (99.7%) JIA subjects, the JIA 
categories were 7.2% with systemic arthritis, 59.5% with 
oligoarthritis, 21.4% with RF negative polyarthritis, 1.4% 
with RF positive polyarthritis, 3.8% with psoriatic arthritis, 
3.5% with enthesitis related arthritis and 3.2% with undif-
ferentiated arthritis (Table 1).
A total of 1372/1396 (98.3%) subjects had the parent ver-
sion of the JAMAR completed by a parent (1274 from par-
ents of JIA patients and 98 from parents of healthy children). 
The JAMAR was completed by 1032/1372 (75.2%) moth-
ers and 340/1372 (24.8%) fathers. The child version of the 
JAMAR was completed by 876/1396 (62.7%) children age 
6.0 or older. Also patients younger than 7 years old, capable 
to assess their personal condition and able to read and write, 
were asked to fill in the patient version of the questionnaire.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median (1st–3rd quartile)] obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers. However, there was no 
significant difference between healthy subjects and their 
affected peers in psychosocial quality of life items.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The follow-
ing results section refers mainly to the parent’s version of 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
For all JAMAR items, the median number of missing 
responses were 0.2% (0.1–0.5%).
The response pattern for both PF and HRQoL was posi-
tively skewed toward normal functional ability and normal 
HRQoL. All response choices were used for the different 
HRQoL items, whereas a reduced number of response 
choices were used for PF items 6 and 15.
The mean and SD of the items within a scale were 
roughly equivalent for the PF and for the HRQoL items, 
except for HRQoL item 5 (data not shown). The median 
number of items marked as not applicable was 9% (2–16%) 
for the PF and 36% (22–59%) for the HRQoL.
Floor and ceiling effect
The median floor effect was 90.9% (85.3–94.3%) for the PF 
items, 69.7% (63.3–73.5%) for the HRQoL PhH items, and 
66.6% (65.5–70.0%) for the HRQoL PsH items. The median 
ceiling effect was 0.2% (0.1–0.4%) for the PF items, 1.7% 
(0.8–2.3%) for the HRQoL PhH items, and 0.7% (0.7–0.7%) 
for the HRQoL PsH items. The median floor effect was 
50.8% for the pain VAS, 46.9% for the disease activity VAS 
and 45.7% for the well-being VAS. The median ceiling effect 
was 0.4% for the pain VAS, 0.7% for the disease activity 
VAS and 0.4% for the well-being VAS.
Equal items–scale correlations (second Likert 
assumption)
Pearson items–scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 87% of the PF 
items, with the exception of PF items 11 and 15, and for 90% 
of the HRQoL items, with the exception of HRQoL item 1.
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Items internal consistency (third Likert assumption)
Pearson items–scale correlations were ≥ 0.4 for 87% of items 
of the PF (except for PF items 11 and 15) and 100% of items 
of the HRQoL.
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.90 for PF-LL, 0.89 for PF-HW, 0.76 
for PF-US. Cronbach’s alpha was 0.87 for HRQoL-PhH and 
0.85 for HRQoL-PsH.
Table 2  Main psychometric characteristics of the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS visual analogue scale, PF physical func-
tion, HRQoL Health Related Quality of Life, PhH physical health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent N = 1274/1372 Child N = 805/876
Missing values (1st–3rd quartiles) 0.2 (0.1–0.5) 0.3 (0.1–0.6)
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 90.9% 92.2%
 HRQoL PhH 69.7% 73.2%
 HRQoL PsH 66.6% 70.4%
 Pain VAS 50.8% 51.3%
 Disease activity VAS 46.9% 50.2%
 Well-being VAS 45.7% 49.1%
Ceiling effect, median
 PF 0.2% 0.1%
 HRQoL PhH 1.7% 1.1%
 HRQoL PsH 0.7% 0.9%
 Pain VAS 0.4% 0.5%
 Disease activity VAS 0.7% 0.6%
 Well-being VAS 0.4% 0.6%
Items with equivalent item-scale correlation 87% for PF, 90% for HRQoL 87% for PF, 90% for HRQoL
Items with items–scale correlation ≥ 0.4 87% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Cronbach’s alpha
 PF-LL 0.90 0.88
 PF-HW 0.89 0.84
 PF-US 0.76 0.72
 HRQoL-PhH 0.87 0.86
 HRQoL-PsH 0.85 0.83
Items with item–scale correlation lower than the Cronbach alpha 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 0.94 0.90
 HRQoL-PhH 0.18 0.70
 HRQoL-PsH 1.0 0.92
Spearman correlation with JIA core-set variables, median
 PF 0.5 0.5
 HRQoL PhH 0.5 0.5
 HRQoL PsH 0.2 0.2
 Pain VAS 0.5 0.4
 Disease activity VAS 0.4 0.4
 Well-being VAS 0.5 0.4
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Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha.
Test–retest reliability
Reliability was assessed in 86 JIA patients, by re-admin-
istering both versions (parent and child) of the JAMAR 
after a median of 2 days (0–5 days). The intraclass cor-
relation coefficients (ICC) for the PF total score showed 
an almost perfect reproducibility (ICC = 0.94). The ICC 
for the HRQoL PhH score showed a poor reproducibility 
(ICC = 0.18) while for the HRQoL PsH score showed an 
almost perfect reproducibility (ICC = 1.0).
Convergent validity
The Spearman correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.4 to 0.6 
(median = 0.5). The PF total score best correlation was 
observed with the parent assessment of pain (r = 0.6, 
p < 0.001). For the HRQoL, the median correlation of the 
PhH with the JIA core set of outcome variables ranged 
from 0.4 to 0.7 (median = 0.5), whereas for the PsH ranged 
from 0.2 to 0.4 (median = 0.2). The PhH showed the best 
correlation with the parent’s assessment of pain (r = 0.8, 
p < 0.001) and the PsH with the parent global assess-
ment of well-being (r = 0.5, p < 0.001). The median cor-
relations between the pain VAS, the well-being VAS, and 
the disease activity VAS and the physician-centered and 
laboratory measures were 0.5 (0.4–0.5), 0.4 (0.3–0.5), 0.5 
(0.4–0.6), respectively.
Discussion
In this study, the Italian version of the JAMAR was cross-
culturally adapted from the original standard English version 
with 3 forward and 2 backward translations. According to 
the results of the validation analysis, the Italian parent and 
patient versions of the JAMAR possess satisfactory psycho-
metric properties. The disease-specific components of the 
questionnaire discriminated well between patients with JIA 
and healthy controls. Notably, there was no significant dif-
ference between the healthy subjects and their affected peers 
in the psychosocial quality of life variable. This finding indi-
cates that children with JIA adapt well to the consequences 
of JIA.
Psychometric performances were good for all domains 
of the JAMAR with few exceptions: PF items 11 and 15 
(“stretch out arms” and “bite a sandwich or an apple”) 
showed a lower items internal consistency. However, the 
overall internal consistency was good for all the domains. 
Notably the ICC for the HRQoL PhH score showed a poor 
reproducibility. In the external validity evaluation, the 
Spearman’s correlations of the PF and HRQoL scores with 
JIA core set parameters ranged from weak to moderate.
The results obtained for the parent version of the JAMAR 
are very similar to those obtained for the child version, 
which suggests that children are equally reliable proxy 
reporters of their disease and health status as their parents. 
The JAMAR is aimed to evaluate the side effects of medi-
cations and school attendance, which are other dimensions 
of daily life that were not previously considered by other 
HRQoL tools. This may provide useful information for inter-
vention and follow-up in health care.
In conclusion, the Italian version of the JAMAR was 
found to have satisfactory psychometric properties and it 
is, thus, a reliable and valid tool for the multidimensional 
assessment of children with JIA.
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